Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodyal is a line of ophthalmic medical devices developed by Omisan Farmaceutici, primarily featuring sodium hyaluronate (hyaluronic acid) as the active lubricant. The product range includes lubricating eye drops and contact lens care solutions designed to alleviate symptoms of dry eye syndrome and enhance comfort for contact lens wearers. Sodium hyaluronate acts as a viscoelastic agent, mimicking natural tears to provide long-lasting hydration and protection to the ocular surface. The Sodyal line includes various formulations, such as Sodyal Plus with a higher concentration of hyaluronate and Sodyal X which utilizes cross-linked hyaluronate for prolonged residence time on the eye. These products are also indicated for the cleaning, disinfection, and maintenance of contact lenses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sodyal.